•Recommended by the latest European Society of Cardiology (ESC) guidelines for myocardial revascularization. •Long term clinical follow-up •Biodegradable Polymer DES •50% reduction in definite stent thrombosis •78% reduction in very late stent thrombosis •Microporous stent surface •Excellent flexibility
-Unique Stent surface which avoid thrombosis and restenosis
-Flexible and Deliverable
-Homogeneous Expansion
-Good side branch access
-Increased Radial Force.
Description:
The Translumina Yukon Choice PC drug-eluting stent, coated with Rapamycin and the biodegradable components polylactide and shellac, has an excellent history of pre-clinical results.
In two independent trials ISAR-TEST 3 and ISAR-TEST 4 the Yukon Choice PC showed angiographic and clinical equivalence with the Cypher stent after 1 year and 3 years of follow-up.
Latest clinical data, shows the excellent long-term outcome of the Yukon Choice PC in a meta-analysis, comparing the clinical outcome after 4 years in more than 4000 patients with the Cypher stent and shows for the first time that the definite Very Late Stent Thrombosis can be reduced statistically significant by using the biodegradable PLA polymer coating technology of the Yukon Choice PC.
